SPDR S&P Pharmaceuticals ETF
XPH
XPH
70 hedge funds and large institutions have $154M invested in SPDR S&P Pharmaceuticals ETF in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 28 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
54% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 28
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $529K
Holders
70
Holding in Top 10
1
Calls
–
Puts
$529K
Top Buyers
| 1 | +$6.45M | |
| 2 | +$2.59M | |
| 3 | +$939K | |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$735K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$633K |
Top Sellers
| 1 | -$18.1M | |
| 2 | -$10.1M | |
| 3 | -$3.54M | |
| 4 |
Jane Street
New York
|
-$1.9M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.88M |